HDAC9 and Parkinson disease: These findings suggest that HDAC5 and HDAC9 may be novel therapeutic targets worthy of further exploration in strategies aimed at axonal protection against α-synuclein-induced damage in iPSC-derived human DA neurons and in vivo models of PD.